Why do patients with BIND keep asking about low-dose naltrexone?
Can low-dose naltrexone help with the symptoms that linger after a benzodiazepine is gone? The honest answer is that nobody knows. Benzodiazepine-induced neurological dysfunction, or BIND, is the name the patient and clinical community uses for the symptoms that can persist for months or years after a benzodiazepine has been tapered and stopped, even when the taper was done carefully.
Burning or tingling skin, a mind that will not hold a thought, sound that hurts, a heart that races at nothing, broken sleep, and a morning dread that lifts by afternoon are the ones patients describe most often. After a year of that, a person will read about anything, and low-dose naltrexone comes up on nearly every patient forum.
It comes up because it has a story attached: that BIND might be sustained by lingering immune activity in the brain, and that this medication, at a very low dose, might quiet it. So, is the story true? The answer is less satisfying than the story.
What is low-dose naltrexone, in plain words?
Naltrexone is an older prescription medication that, at full strength, blocks a receptor system that has nothing to do with the GABA receptors where benzodiazepines act. GABA stands for gamma-aminobutyric acid, the brain’s main calming signal, and the whole benzodiazepine problem lives there. Naltrexone does not touch it.
Low-dose naltrexone, or LDN, means the same medication given at a small fraction of its full strength. At that fraction, the thinking goes, it does something different, and that difference is why anyone is interested.
The United States Food and Drug Administration (FDA) label for naltrexone describes the full-strength tablet and its approved uses, and it says nothing about the very low doses used as LDN. Every low-dose use is off-label, which is legal and common, and it means the label cannot tell you much about what to expect.
The name puts some people off, and it should not.
At full strength, naltrexone has a long history in addiction medicine, for unrelated conditions, and some patients hear the name and hear an accusation. While that reaction is understandable, the premise behind it is wrong.
Physical dependence is not addiction. Dependence is what a nervous system does when a medication has been present long enough for the brain to adapt around it, and it happens to people who never once misused a pill. A low dose of this medication for a different purpose says nothing about you either.
What is the theory that connects it to BIND?
Chapter III of the Ashton Manual, on withdrawal symptoms, sets out in its Table 4 the possible causes of protracted symptoms. Nervous system hyperexcitability from persisting changes in GABA and benzodiazepine receptors is listed there without a question mark, while structural or functional damage to brain tissue and changes in the gut and immune systems carry one, which the table defines as a mechanism with no scientific evidence yet.
Yet, the same chapter notes that benzodiazepine use or withdrawal may affect immune responses. One theory in the patient and clinical community runs with that thread: perhaps the brain’s own immune cells, activated during long exposure and withdrawal, stay activated and keep the nervous system on edge after the receptors should have recovered.
A rough analogy, and an imperfect one, is a house where the fire is out but the smoke alarm will not stop. The fire was the benzodiazepine, the alarm is the immune activity, and LDN is proposed as a way to reset the alarm. While this is not a perfect analogy, it tells you what to expect at best: a quieter alarm, never a rebuilt house, and no shorter wait for the rebuilding.
Is there any evidence that it works for BIND?
No. There are no studies of low-dose naltrexone in BIND that anyone can point to, and none in protracted benzodiazepine withdrawal. The immune theory is a hypothesis, and a hypothesis with a good story is still a hypothesis.
Medicine is full of plausible mechanisms that never became treatments. Unfortunately, the science behind LDN in BIND has not been done, and what exists instead is clinical experience, which varies.
What do patients who have tried it report?
A common pattern goes like this. A patient a year or two off a benzodiazepine, still living with burning skin and a mind that will not settle, tries LDN under a physician’s care and reports, a few weeks in, that the pain sits a little further away and the mornings are less dreadful. Nothing dramatic, but a change worth keeping.
Just as common is the other pattern. The same kind of patient starts LDN and, within days, reports vivid dreams, worse sleep, a wired restlessness, or a wave of anxiety and nausea. A sensitized nervous system reacts to almost every new input, and some of those patients decide, sensibly, that it is not for them.
A bad first week does not mean a person did anything wrong. And, a good month does not prove the medication did it, because BIND improves on its own over time, unevenly, so both patients above may be right about what they felt and wrong about why.
What does the medication’s own label say you should know?
The naltrexone label describes the full-strength tablet, and its cautions are written for that strength, yet some matter at any dose. It advises carrying identification saying you take naltrexone and telling every physician who treats you, because certain prescription pain medicines used after surgery or injury may not work while it is in your system. Say so to your surgeon and your dentist before a procedure, not after.
Beyond that, the label warns of liver injury and advises seeking medical attention for symptoms of hepatitis, so your doctor should know your liver history before prescribing any strength. Among the most common side effects it lists at full strength are nausea, headache, dizziness, nervousness, fatigue, insomnia, and anxiety, a list that reads like BIND itself, which is why a person with BIND cannot always tell a side effect from a wave.
If a new symptom is chest pain, a seizure, a sudden loss of vision or hearing, or thoughts of harming yourself, that is emergency care today, whatever else you are trying, and the 988 Suicide and Crisis Lifeline is there for the last of those.
It has to be compounded, and it has to be reviewed.
Low-dose naltrexone is not a product you can pick up at a chain pharmacy. The doses used are a small fraction of the manufactured tablet, so a compounding pharmacy has to make it, from a prescription written by a physician who has decided, with you, that a trial is reasonable. In practice, that means it is not a self-help project, and it means being wary of anyone selling it outside that arrangement.
The decision is individualized, weighing the symptoms, how reactive the nervous system has been to other inputs, what else is being taken, and what has already been tried, and some patients will not be candidates at all. Every reasonable trial has review points. The cautious position is that a trial should have a date on which patient and physician decide together whether it is helping, and that it should be as easy to stop as it was to start.
An open-ended trial with no decision rule is how a person ends up on a medication for two years without knowing whether it did anything.
It never replaces a slow taper, and it does not buy back time.
If you are still taking a benzodiazepine, low-dose naltrexone is not a shortcut. It does not treat withdrawal, and it is never a reason to speed up a taper or to stop abruptly. The Maudsley Deprescribing Guidelines describe protracted withdrawal syndromes lasting months or years after benzodiazepines and recommend a slow, hyperbolic taper adjusted to what the person can tolerate, and no adjunct changes that.
The 2020 FDA benzodiazepine label update acknowledged a protracted withdrawal syndrome whose symptoms may last weeks to as long as 12 months. Professor Ashton wrote, in the same chapter of the Manual, that a steady decline in symptoms almost invariably continues after withdrawal, though it can take a long time, even several years in some cases. Time is the one treatment for BIND that everyone agrees on, and no adjunct has been shown to shorten it.
So, the most that can be hoped from LDN is that some symptoms sit a little further away while the slow work goes on underneath. For a person in pain that is worth something, and it is a long way from a cure.
So, where does that leave you?
Is a cautious, reviewed trial of a low-dose medication worth trying for symptoms that have already lasted a long time? Some patients and their physicians will decide yes, some will decide no, and neither is the wrong decision on the evidence we have.
Your doctor wants to hear the question, and a doctor who has seen BIND will not be surprised by it. Bring the label’s cautions, your own history of reactions to new medications, and a willingness to stop if it is not helping. Fortunately, the recovery that matters is already under way, with or without any of this.
This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.